Wolfe Research initiated coverage of Tyra Biosciences with a Peer Perform rating an no price target. Tyra has dabogratinib in development for bladder cancer and achondroplasia, notes the analyst, who sees the drug as likely to \"achieve the CR bar for LR IR NMIBC,\" but is \"on the fence\" until seeing safety de-risking. The pipeline supports the long-term thesis, though current levels limit near-term upside, the analyst added.
